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Question
Recently, several cases of seizure seconda-
ry to hyponatremia have been reported in 
children treated with intranasal DDAVP1), 2). 
This has rarely been reported with the 
oral form. Should the intranasal form be 
banned for the treatment of nocturnal en-
uresis (NE)? Or should any form of DDAVP 
be banned? What are the precautions to 
take to avoid such an event? We hereunder 
summarize the literature on the subject, 
and present the recommendations of the 
Swiss Group for Pediatric Nephrology and 
the current position of Swiss medic. 
Answer
1. Introduction
NE is a fairly common benign developmen-
tal disorder, most of the time self-limited, 
encountered more frequently in boys than 
girls, with a high rate of spontaneous reso-
lution (approximately 15% per year from the 
age of 6). In case of a protracted course or 
in particular situations (sport camp partici-
pation, sleepover), numerous approaches 
have bee tried, with various success, such 
as: behavioral therapy3), DDAVP analogs 
(Minirin®, Nocutil®)4), nocturnal alarm5) or 
tricyclic antidepressant6). We here review 
these therapeutic modalities, their success 
rate and associated side effects. We also 
compare data available in the literature 
comparing the oral form with the intranasal 
form for Minirin®, especially regarding the 
occurrence of hyponatremia.
2. Pharmacological and non-
pharmacological treatment of NE
Because of its psychological repercussion, 
physician will often be asked to start treat-
ment, rather than wait for spontaneous 
resolution. This is especially true for slee-
pover or sport camp participation, in which 
situations nocturnal enuresis can be fru-
strating for the child7). Desmopressin, also 
known as DDAVP, is a synthetic analogue of 
AVP. Desmopressin increases tubular reab-
sorption of water in the collecting ducts, 
and decreases the nocturnal urine volume. 
Its current indications include: NE and 
central diabetes insipidus. Desmopressin 
is commercially available as an intranasal 
solution (introduced 1972), an injectable 
solution for intravenous, subcutaneous or 
intramuscular use (introduced 1981), an 
oral tablet formulation (introduced 1987) or 
a rapidly acting, water-free oral lyophylisate 
formulation (introduced 2005). In several 
randomized trials, DDAVP has been shown 
to rapidly reduce the number of wet night 
per week, although there is some evidence 
that this was not sustained after treatment 
stopped4). The different formulas share the 
same physiological properties, with different 
bioavailability, and hence different dosages 
(commonly 0.1 μg for the IV route (not 
used for NE), 10–40 μg for the nasal route, 
0.1–0.4 mg for the oral route and 60–240 
μg for the sublingual route. It should be 
noted that published pharmacological data 
were obtained in adults and that the doses 
used in children were extrapolated from the-
se studies. Studies in healthy adults show 
that the antidiuretic activity of therapeutic 
dosage of DDAVP nasal spray and tablets 
last for 6 to 24 hours8) and 6 to 8 hours9), 
respectively. The slightly longer duration 
action of the intranasal formulation might 
explain the observed tendency of this parti-
cular form to induce hyponatremia.
Other pharmacological treatments of NE 
include tricyclic agents. Two small studies 
showed no superiority of imipramine10) or 
amitriptyline11) over desmopressin. Because 
of their very narrow therapeutic index and 
potential lethal adverse effects (cardiac 
arrhythmia)12), we feel that tricyclic agents 
should not be prescribed in children with 
isolated NE. 
Non-pharmacological treatment of NE in-
cludes behavioral therapy and nocturnal 
alarm. Very few studies compared desmo-
pressin and nocturnal alarm. In a single 
trial, Faraj et al.13) found desmopressin to 
offer better short-term results than enuresis 
alarm but the latter was significantly more 
efficient in the long term. Glazener et al., in 
a complete literature analysis, also found 
nocturnal alarm to be more effective than 
desmopressin or tricyclics by the end of 
treatment, and subsequently5). A thorough 
discussion of behavioral therapy is beyond 
the scope of this short review. 
3. Desmopressin and the risk 
of hyponatremia
3.1. Review of the literature
DDAVP has been used extensively, in mil-
lions of children, for more than 30 years, 
and has been found to have a very good 
safety profile. Side effects are rare. Hy-
ponatremia is one of the most commonly 
reported side effect, and potentially the 
most severe one14). Recent data suggest 
that there might be a increased risk of hypo-
natremia with the intranasal DDAPV formu-
lation compared to the oral formulation15). It 
is unclear at this point why patients taking 
the intranasal DDAVP formulation should 
develop more often hyponatremia than 
patients on the oral formulation. Robson 
et al.15) raises interesting hypothesis such 
as: repeated dose if the parents felt unsure 
whether an adequate dose has been admi-
nistered, increased bioavailability in case 
of nasal mucosa inflammation/rhinitis and 
prolonged antidiuretic activity compared to 
the oral form. All these factors might explain 
the observed increased risk of hyponatre-
mia with the intranasal form.
Identifiable and preventable risk factors for 
hyponatremia, common to both the oral and 
the intranasal forms, are: inappropriately 
high fluid intake prior to DDAVP, administra-
tion of a larger than recommended dose of 
DDAVP, young age (less than 6 years) and 
concomitant administration of another me-
dication (NSAID). 
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When desmopressin is prescribed, the pa-
tient and the parents should be carefully 
instructed to avoid high fluid intake when 
the medication is taken (i.e., the child 
should have no fluid intake after the drug 
administration in the evening until the next 
morning), not to give a higher than recom-
mended dose, and to promptly discontinue 
the medication and seek assessment if 
headache, nausea or vomiting develops.
3.2. Hyponatremia and DDAVP 
reported to SwissMedic
All patients with symptomatic hyponatremia 
reported to Swiss medic are compiled in 
table 1. For pediatric patients, it is remarka-
ble to note that all the patients were quite 
young; all of them on the intranasal formu-
lation, and most of them had developed 
hyponatremia very soon (1–2 days) after in-
itiation of therapy. These are the known and 
reported risk factors for hyponatremia with 
DDAVP which are: young age, intranasal 
formulation, and recent initiation of therapy 
(or change in drug dosage)1). 
Postmarketing reports of serious hyponatre-
mia events have so far been more frequent 
for the nasal forms than for the oral forms 
of Desmopressin. The indication enuresis 
nocturna has therefore been withdrawn 
from the market in Switzerland for the nasal 
forms of Desmopressin. 
One should however keep in mind that the 
removal of the indication for the nasal forms 
is based on spontaneous reports, which 
means that the actual number of events 
is an underestimate (not all events are 
reported) and that despite approximations 
from sales figures the exact exposure is 
also unknown. Without knowing the actual 
number of events and the exact exposure, 
it is not possible to directly compare the in-
cidence of serious hyponatremias under the 
oral as compared to the nasal forms. Of note 
is also that the oral forms have been on the 
market for a shorter duration than the intra-
nasal forms. It is therefore very important 
to report any hyponatremia-related adverse 
event that may be observed in the future 
with the oral forms of desmopressin.
Conclusions
1)  Desmopressin (nasal or oral) and noctur-
nal alarm probably have the same effica-
cy, although nocturnal alarm might have 
a lower relapse rate on the long term. If 
parents or physician are concerned with 
potential drug side effect, nocturnal alarm 
should be the first therapeutic option.
2)  Both the intranasal and oral desmo-
pressin forms have been associated 
with severe hyponatremia secondary to 
water intoxication. However, the data 
are now suggesting that hyponatremia 
occurs more often with the intranasal 
DDAVP formulation than with the oral 
formulation.
3)  Thus, the NE indication for the intra-na-
sal form was recently withdrawn from 
the market in Switzerland. It should be 
known that the intranasal form has been 
previously withdrawn from its NE indica-
tion in Italy, France, UK, Spain, Portugal, 
Austria and Greece.
4)  If the parents and the physician opt 
for drug therapy, the oral DDAVP for-
mulation (oral or sublingual) will be 
administered. The efficacy of the two 
drug formulations have been shown to 
be similar.
5)  When taking DDAVP, whichever formula-
tion, the patient and the parents should 
be warned of potential side effects, and 
instructed accordingly: 
●	 To strictly adhere to the dosage that 
has been recommended.
●	 To avoid drinking after the drug ad-
ministration in the evening until the 
next morning
Table 1: summary of patients with hyponatremia reported to Swissmedic as of 02.08.2007
Legend: C: coma, EN: enuresis nocturna, H: headache, Na: nausea, N: intranasal, O: oral, Pit. adenoma: pituitary adenoma, R: recovered, S: seizures, Somn.: somnolence, 
V: vomiting.
 Age (years) Diagnosis Symptoms  Form  Dosage Duration of therapy Outcome
 11 EN H, V, S N 10 μg 1 day R
 8 EN S N 20 μg 3 days R
 6 EN S N 20 μg 14 days R
 12 EN Somn. N 40 μg 2 days R
 7 EN Somn., S N 50 μg 53 days R
 9 EN Somn., V N 20 μg 5 days R 
 7 EN S, C N 20 μg 1 day R
 9 EN Na, H, S N 20 μg 1 day R
Ch
ild
er
n
 Age (years) Diagnosis Symptoms  Form  Dosage Duration of therapy Outcome
 58 Pit. adenoma Somn. O 0.3 mg unknown R
 70 Potomania, Somn. O 0.1 mg 2 days R
  Parkinson
 61 Pit. adenoma Na, V, Somn. N 10 μg unknown R
 63 Nycturia Somn. N unknown unknown unknown
 83 Incontinence Somn. N 10 μg 3 months R
 67 EN V N 40 μg 2 days R
Ad
ul
ts
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●	 To immediately stop DDAVP admi-
nistration and seek medical help 
should the child present any signs 
or symptoms suggestive of water 
intoxication such as: headaches, 
nausea, vomiting, confusion, altered 
consciousness or seizure.
These recommendations apply especially 
to the young child, in the first few weeks of 
treatment or after drug dosage adjustment, 
or in case of concomitant drug administrati-
on (NSAID) or in case of associated disorder 
such as cystic fibrosis1), 16). 
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